Ocrelizumab accepted for EMA review
Ocrelizumab accepted for EMA review
Roche has announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorisation Application (MAA) of ocrelizumab for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) in the European Union (EU)...Read more - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 9054 Views
-
Last post by NHE
-
- 0 Replies
- 931 Views
-
Last post by NHE
-
- 0 Replies
- 1746 Views
-
Last post by frodo
-
- 0 Replies
- 1100 Views
-
Last post by frodo
-
- 0 Replies
- 1845 Views
-
Last post by NHE
-
- 0 Replies
- 1575 Views
-
Last post by frodo
-
- 0 Replies
- 1108 Views
-
Last post by NHE
-
- 1 Replies
- 1496 Views
-
Last post by frodo
-
- 0 Replies
- 2110 Views
-
Last post by NHE